Pershing Edward - 30 Jun 2026 Form 4 Insider Report for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)

Reporting relationship: CEO, Director, 10%+ Owner
Issuer ticker: PVCT
Reported as of: 30 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jul 2026, 12:39:22 UTC
Prior SEC filing: 05 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Ed Pershing

Key filing fact

Pershing Edward filed Form 4 for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) on 02 Jul 2026.

Key facts

This page summarizes Pershing Edward's Form 4 filing for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Jul 2026, 12:39.

Change

Previous filing in this sequence was filed on 05 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001689739 Primary reporting owner

Pershing Edward

Relationship: CEO, Director, 10%+ Owner
Address: 800 S. GAY STREET,, SUITE 1610, KNOXVILLE
Signature: /s/ Ed Pershing
Signature date: 02 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PVCT transaction Derivative

Series D-1 Convertible Preferred Stock

Award

Transaction value
Shares: +45,860
Change %: +1.6%
Price: $0.000000^*
Shares after: 2,866,761
Date: 30 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 458,600
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").

Footnote F2

The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

Footnote F3

The amount reported reflects an adjustment to correct a typographical error in a previously filed Form 4. This adjustment does not reflect a transaction by the Reporting Person.